Validation of a novel CHX-A″ derivative suitable for peptide conjugation: Small animal PET/CT imaging using yttrium-86-CHX-A″- octreotide

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4297-4304

  Clifford, Thomas ^a,c   Boswell, C Andrew ^a   Biddlecombe, Gráinne B ^b   Lewis, Jason S ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Morphix Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; INDIUM; LUTETIUM; OCTREOTIDE; OCTREOTIDE[CYCLOHEXYLDIETHYLENETRIAMINEPENTETIC ACID Y 86]; PENTETIC ACID; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT;

ANIMALS; ISOTHIOCYANATES; ISOTOPE LABELING; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 33745834770     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060317v     Document Type: Article

References (55)

1. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discovery 2004, 3, 488-499.
2. 90Y using a bifunctional DTPA chelating agent. Cancer Biother. Radiopharm. 2003, 18, 355-363.
3. Parry, R.; Schneider, D.; Hudson, D.; Parkes, D.; Xuan, J.; Newton, A.; Toy, P.; Lin, R.; Harkins, R.; Alicke, B.; Biroc, S.; Kretschmer, P. J.; Halks-Miller, M.; Klocker, H.; Zhu, Y.; Larsen, B.; Cobb, R. R.; Bringmann, P.; Roth, G.; Lewis, J. S.; Dinter, H.; Parry, G. Identification of a novel prostate tumor target, Mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 2005. 65, 8397-8405.
4. 90Y-CHX- A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin. Cancer Res. 2005, 11, 7080-7086.
5. Chong, H. S.; Garmestani, K.; Ma, D. S.; Milenic, D. E.; Overstreet, T.; Brechbiel, M. W. Synthesis and biological evaluation of novel macrocyclic ligands with pendant donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J. Med. Chem. 2002, 45, 3458-3464.
6. 90Y labeling of proteins. Nucl. Med. Biol. 1992, 19, 239-244.
7. Ruegg, C. L.; Anderson-Berg, W. T.; Brechbiel, M. W.; Mirzadeh, S.; Gansow, O. A.; Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990, 50, 4221-4226.
8. Milenic, D. E.; Roselli, M.; Mirzadeh, S.; Pippen, C. G.; Gansow, O. A.; Colcher, D.; Brechbiel, M. W.; Schlom, J. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother. Radiopharin. 2001, 16, 133-146.
9. 2DTPA) complexes. Inorg. Chem. 1996, 35, 6343-6348.
10. Wu, C.; Kobayashi, H.; Sun, B.; Yoo, T. M.; Paik, C. H.; Gansow, O. A.; Carrasquillo, J. A.; Pastan, I.; Brechbiel, M. W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Biaorg. Med. Chem. Lett. 1997, 5, 1925-1934.
11. Kobayashi, H.; Wu, C. C.; Yoo, T. M.; Sun, B. F.; Drumm, D.; Pastan, I.; Paik, C. H.; Gansow, O. A.; Carrasquillo, J. A.; Brechbiel, M. W. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med. 1998, 39, 829-836.
12. Milenic, D. E.; Garmestani, K.; Brady, E. D.; Albert, P. S.; Ma, D. S.; Abdulla, A.; Brechbiel, M. W. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 2004, 10, 7834-7841.
13. 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. 2005, 20, 557-568.
14. Li, W. P.; Meyer, L. A.; Anderson, C. J. Contrast agents III: Radiopharmaceuticals - From diagnostics to therapeutics. Top. Curr. Chem. 2005, 252, 179-192.
15. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev. 2003, 24, 389-427.
16. Blok, D.; Feitsma, R. I. J.; Vermeij, P.; Pauwels, E. J. K. Peptide radiopharmaceuticals in nuclear medicine. Eur. J. Nucl. Med. 1999, 26, 1511-1519.
17. Heppeler, A.; Froidevaux, S.; Eberle, A. N.; Maecke, H. R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 2000, 7, 971 -994.
18. Reichlin, S. Somatostatin (part 1). N. Engl. J. Med 1983, 309, 1495-1501.
19. Reichlin, S. Somatostatin (part 2). N. Engl. J. Med. 1983, 309, 1556-1563.
20. Reubi, J. C.; Kvols, L. K.; Krenning, E. P.; Lamberts, S. W. J. Distribution of Somatostatin receptors in normal and tumor tissue. Metabolism (supplement 2) 1990, 39, 78-81.
21. Dasgupta, P. Somatostatin analogs: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther. 2004, 102, 61-85.
22. 3- octreotide. J. Med. Chem. 2005, 48, 1506-1514.
23. Wang, W.; McMurray, J. S.; Wu, Q.; Campbell, M. L.; Li, C. Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)-conjugated cyclic RGD peptide analogs. Cancer Biother. Radiopharm. 2005, 20, 547-556.
24. Brechbiel, M. W.; Gansow, O. A.; Atcher, R. W.; Schlom, J.; Esteban, J.; Simpson, D. E.; Colcher, D. Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 1986, 25, 2772-2781.
25. Mirzadeh, S.; Brechbiel, M. W.; Atcher, R. W.; Gansow, O. A. Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjugate Chem. 1990, 1, 59-65.
26. Song, A. I.; Rana, T. M. Synthesis of an amino acid analog to incorporate p-aminobenzyl-EDTA in peptides. Bioconjugate Chem. 1997, 8, 249-252.
27. Riddoch, R. W.; Schaffer, P.; Valliant, J. F. A solid-phase labeling strategy for the preparation of technetium and rhenium bifunctional chelate complexes and associated peptide conjugates. Bioconjugate Chem. 2006, 17, 226-235.
28. +]G. Bioconjugate Chem. 2004, 15, 128-136.
29. Stimmel, J. B.; Stockstill, M. E.; Kull, F. C. Y-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogs, and a novel terpyridine acyclic chelator. Bioconjugate Chem. 1995, 6, 219-225.
30. Boswell, C. A.; Brechbiel, M. W. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J. Nucl. Med. 2005, 46, 1946-1947.
31. 1-octreotide: A case history. Ann. N.Y. Acad. Sci. 1994, 733, 496-506.
32. 1-octreotide in midgut carcinoid syndrome. J. Nucl. Med. 1996, 37, 1519-1521.
33. 111In-DTPA-D-Phe]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991, 49, 1583-1591.
34. 111In-DTPA-D-Phe]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 1991, 49, 1593-1601.
35. 3-octreotide. J. Nucl Med. 1992, 33, 652-658.
36. Rolleman, E. J.; Valkema, R.; de Jong, M.; Kooij, P. P. M.; Krenning, E. P. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 9-15.
37. Stolz, B.; Smith-Jones, P.; Albert, R.; Tolcsvai, L.; Briner, U.; Ruser, G.; Macke, H.; Weckbecker, G.; Bruns, C. Somatostatin analogs for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996, 57, 17-21.
38. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur. J. Nucl. Med. 1998, 25, 668-674.
39. Otte, A.; Muellerbrand, J.; Dellas, S.; Nitzsche, E. U.; Herrmann, R.; Maecke, H. R. Yttrium-90-labeled somatostatin analog for cancer treatment. Lancet 1998, 351, 417-418.
40. 3-octreotide (SMT487) - A Phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. 2003, 30, 510-518.
41. Mansi, L. From the magic bullet experience to an effective therapy: The peptide experience. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1393-1398.
42. Goddu, S. M.; Rao, D. V.; Howell, R. W. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J. Nucl. Med. 1994, 35, 521-530.
43. 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J. Nucl. Med. 1999, 40, 268-276.
44. 90Y-labeled anti-Lewis Y monoclonal antibody B3. Clin. Cancer Res. 2000, 6, 1720-1730.
45. 90Y radiotherapeutics. J. Nucl Med. 1993, 34, 2222-2226.
46. 86Y for nuclear medicine application. Appl. Radiat. Isot. 1993, 44, 677-681.
47. 111In labeled Herceptin. Nucl. Med. Biol. 2002, 29, 599-606.
48. 86Y purification using a three-column system. Nucl. Med. Biol. 2004, 31, 297-301.
49. 86Y. Radiochim. Acta 2002, 90, 225-228.
50. 86Y using a small biomedical cyclotron. Nucl. Med. Biol. 2005, 32, 891-897.
51. 11), a cyclized peptide analogue of α-MSH. J. Med. Chem. 2005, 48, 2985-2992.
52. 64Cu-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med. Chem. 2004, 47, 1465-1474.
53. 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clin. Cancer Res. 1999, 5, 3608-3616.
54. 111In-pentetreotide in rats. J. Nucl. Med. 1995, 36, 623-627.
55. Norenberg, J. P.; Krenning, B. J.; Konings, I. R. H. M.; Kusewitt, D. F.; Nayak, T. K.; Anderson, T. L.; de Jong, M.; Garmestani, K.; Brechbiel, M. W.; Kvols, L. K. Bi-213-[DOTA(0),Tyr(3)]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res. 2006, 12, 897-903.